

References

1. Pizzi LT, Lofland JH. *Economic Evaluation in U.S. Health Care: Principles and Applications*: 2005: Jones & Bartlett Publishers.
2. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? *Cost Eff Resour Alloc*. 2008;6:9.
3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis*, 2000. 20(1): p. 1-16.
4. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. *AIDS*, 2004. 18(17): p. 2295-303.
5. AIDS epidemic update 2007, World Health Organization.
6. Annual Surveillance Report: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. 2007, National Centre in HIV Epidemiology and Clinical Research. Available at: [http://www.ncheer.unsw.edu.au/NCHECRweb.nsf/resources/Publications_3/\\$file/pub-nonpeer-rev.pdf](http://www.ncheer.unsw.edu.au/NCHECRweb.nsf/resources/Publications_3/$file/pub-nonpeer-rev.pdf)
7. Ball AL, Rana S, Dehne KL. HIV prevention among injecting drug users: responses in developing and transitional countries. *Public Health Rep* 1998. 113: p. 170-181.
8. Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, Soto J et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. *Am J Epidemiol* 1997. 146(12): p. 994-1002.
9. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. *Am J Epidemiol* 1999. 149(3): p. 203-13.
10. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. *Am J Epidemiol* 1994. 139: p. 1153-1163.
11. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. *Lancet* 1997. 349(9068): p. 1797-800.
12. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. *Subst Use Misuse*, 2006. 41: p. 777-813.
13. Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. *Soc Sci Med* 2000. 51(12): p. 1771-82.
14. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. *Public Health Rep* 1998. 113 Suppl 1: p. 75-80.
15. Heimer R. Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond. *Public Health Rep* 1998. 113 Suppl 1: p. 67-74.
16. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. *AIDS* 2001. 15: p. 1329-1341.
17. Kidorf M, King VL. Expanding the public health benefits of syringe exchange programs. *Can J Psychiatry* 2008. 53(8): p. 487-95.
18. Des Jarlais C, Perlis T, Friedman SR, Chapman T, Kwok J, Rockwell R et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. *Am J Public Health* 2000. 90(7): p. 1112-6.
19. Donoghoe MC, Stimson GV, Dolan K, Alldritt L. Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. *AIDS* 1989. 3(5): p. 267-72.
20. Wodak A, Dolan K, Imrie AA, Gold J, Wolk J, Whyte BM et al. Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. *Med J Aust* 1987. 147(6): p. 275-6.
21. Feachem RGA. Valuing the past... Investing in the future. Evaluation of the National HIV/AIDS Strategy 1993-94 to 1995-96. AGPS, Canberra. 1995.
22. Needle and syringe programs: position paper. 2002: Australian National Council on Drugs.

23. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G et al. Modelling the hepatitis C virus epidemic in Australia. *Drug Alcohol Depend* 2007. 91(2-3): p. 228-35.
24. Return on Investment in Needle and Syringe Programs in Australia Report. 2002, Commonwealth Department of Health and Ageing, Health Outcomes International Pty Ltd, National Centre in HIV Epidemiology and Clinical Research: Sydney, Australia.
25. Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. A review of the effectiveness and cost-effectiveness of needle and syringe programmes for injecting drug users. 2006, Centre for Public Health, Liverpool, John Moores University: Liverpool, UK.
26. Cohen DA, Wu SY, Farley TA. Structural interventions to prevent HIV/sexually transmitted disease: Are they cost-effective for women in the Southern United States? *Sexually Transmitted Diseases* 2006. 33(7 SUPPL.).
27. Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. *J Acquir Immune Defic Syndr* 2004. 37(3): p. 1404-14.
28. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998. 18(SUPPL.): p. S133-S138.
29. Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. *AIDS* 1998. 12 Suppl A: p. S217-30.
30. Vickerman P, Miners A, Williams A. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: An economic modelling report. 2008, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine: London.
31. Cabases JM, Sanchez E. Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting. *European Journal of Health Economics* 2003. 4(3): p. 203-208.
32. Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: an economic evaluation of a local experience. *Cmaj*, 1997. 157(3): p. 255-62.
33. Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T. Cost effectiveness of Streetworks' needle exchange program of Edmonton. *Can J Public Health* 1999. 90(3): p. 168-71.
34. Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov C, Emelyanova Z et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. *Addiction* 2004. 99(12): p. 1565-76.
35. Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. *J Acquir Immune Defic Syndr* 2001. 28(3): p. 273-278.
36. Harris ZK. Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program. *Health Econ* 2006. 15(2): p. 147-58.
37. Pinkerton SD, Holtgrave DR, DiFranceisco W, Semaan S, Coyle SL, Johnson-Masotti AP. Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions. *AIDS* 2000. 14(9): p. 1257-68.
38. Vickerman P, Kumaranayake L, Balakireva O, Guinness L, Artyukh O, Semikop T et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. *Sex Transm Dis* 2006. 33(10 Suppl): p. S89-102.
39. Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. *Med Decis Making* 2001. 21(5): p. 357-67.
40. Hoare A, Regan DG, Wilson DP. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. *Theor Biol Med Model* 2008. 5: p. 4.
41. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Epidemic in Australia. 2006, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales: Sydney, Australia.
42. Medicare Australia. MBS online. 2008 24 October 2008]; Available from: <http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1>.

43. Department of Health and Ageing. Pharmaceutical Benefits Schedule. 2008 24 october 2008]; Available from: <http://www.pbs.gov.au/html/healthpro/home>.
44. Department of Health and Ageing. National Admitted Patient Care Collection (NAPCC) 2004-05. Clinical Profiles 2004-05. 2005 24 Nov 2008]; Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/NAPCC-data_2004-05_cppub.
45. Department of Health and Ageing. Round 11 (2006-07) Cost Report - Public version 5.1., 2007; Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/Round_11-cost-reports.
46. Carole A. Federico, Priscilla C. Vuong, Mel Krajden, Eric M et al. Patient Time Costs and Out-of-Pocket Costs in Hepatitis C. Vancouver, British Columbia, Canada: British Columbia Centre for Disease Control. 2009.
47. Bowie RD, Tobias MI, Williams T. The private costs of HIV/AIDS. N Z Med J 1996. 109: p. 51-54.
48. Organisation for Economic Cooperation and Development. Purchasing Power Parity. 2008. Available from: <http://www.oecd.org/dataoecd/61/54/18598754.pdf> (Accessed 20 February, 2009).
49. Dwyer R, Power R, Topp L, Maher L, Conroy A, Jauncey M et al. IRID report: An exploratory study of non-viral injecting-related injuries and diseases among Australian injecting drug users. 2007, Centre for Epidemiology and Population Health Research, Burnet Institute: Melbourne.
50. Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend 2009. 100(1-2): p. 9-16.
51. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of Health Care Programs. 2005, Oxford: Oxford University Press.
52. Department of Human Services, Victorian Burden of Disease Study. 2001, Department of Human Services, Melbourne.
53. Guy R, Devadason D, Lim M, Higgins N, Pedrana A, Gibson K et al. Enhanced case detection for newly acquired hepatitis C infection: epidemiological findings and health service implications. Commun Dis Intell., 2008. 32: p. 250-256.
54. Iversen J, Topp L, Maher L. Australian NSP Survey National Data Report 2002--2006, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2007.
55. Islam M, Wodak A, Conigrave KM. The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings. Int J Drug Policy 2008. 19: p. 436-441.
56. O'Brien S, Black E, Degenhardt L, Roxburgh A, Campbell G, de Graaff B et al. Australian Drug Trends 2006: Findings from the Illicit Drug Reporting System (IDRS). 2006, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
57. Topp L, Darke S, Bruno R, Fry C, Hargreaves K, Humeniuk R et al. Australian Drug Trends 2000: Findings of the Illicit Drug Reporting System (IDRS). 2000, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
58. Topp L, Kaye S, Bruno R, Longo M, Williams P, O'Reilly B et al. Australian Drug Trends 2001: Findings of the Illicit Drug Reporting System (IDRS). 2001, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
59. Breen C, Degenhardt L, Roxburgh A, Bruno R, Duquemin A, Fetherston J et al. Australian Drug Trends 2002: Findings from the Illicit Drug Reporting System (IDRS). 2002, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
60. Breen C, Degenhardt L, Roxburgh A, Bruno R, Fetherston J, Jenkinson R et al. Australian Drug Trends 2003: Findings from the Illicit Drug Reporting System (IDRS). 2003, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
61. Stafford J, Degenhardt L, Black E, Bruno R, Buckingham K, Fetherston J et al. Australian Drug Trends 2004: Findings from the Illicit Drug Reporting System (IDRS). 2004, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
62. Stafford J, Degenhardt L, Black E, Bruno R, Buckingham K, Fetherston J et al. Australian Drug Trends 2005: Findings from the Illicit Drug Reporting System (IDRS). 2005, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

63. Kwon JA, Iversen J, Maher L, Law M, Wilson DP. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. *J Acquir Immune Defic Syndr* 2009. In press.
64. Anderson RM, May RM. *Infectious Diseases of Humans: Dynamics and Control*. 1991, NY: Oxford University Press.
65. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. *Addiction* 2006. 101(10): p. 1499-508.
66. 2007 National Drug Strategy Household Survey: first results. 2008, Australian Institute of Health and Welfare: Canberra.
67. Falster K, Kaldor JM, Maher L. Hepatitis C Virus Acquisition among Injecting Drug Users: A Cohort Analysis of a National Repeated Cross-sectional Survey of Needle and Syringe Program Attendees in Australia, 1995–2004. *Journal of Urban Health*, 2009. In press.
68. Hagan H, Pouget ER, Des Jarlais DC, Lelutia-Weinberger C. Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place. *Am J Epidemiol* 2008. 168: p. 1099-1109.
69. Donoghoe MC, Dolan KA, Stimson GV. Life-style factors and social circumstances of syringe sharing in injecting drug users. *Br J Addict* 1992. 87(7): p. 993-1003.
70. McKeganey N, Abel M, Taylor A, Frischer M, Goldberg D, Green S. The preparedness to share injecting equipment: an analysis using vignettes. *Addiction* 1995. 90(9): p. 1253-60.
71. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. *N Engl J Med* 1994. 331(6): p. 341-6.
72. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. *Am J Epidemiol* 1997. 146(4): p. 350-7.
73. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. *Am J Epidemiol* 1999. 150(3): p. 306-11.
74. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. *Lancet* 2001. 357(9263): p. 1149-53.
75. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O et al. Rates of HIV-1 Transmission per Coital Act, by Stage of HIV-1 Infection, in Rakai, Uganda. *J Infect Dis* 2005. 191(9): p. 1403-9.
76. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K et al. Risk factors for HIV infection among men who have sex with men. *AIDS* 2006. 20(5): p. 731-9.
77. Read TRH, Hocking J, Sinnott V, Hellard M. Risk factors for incident HIV infection in men having sex with men: a case-control study. *Sexual Health* 2007. 4: p. 35-39.
78. Grierson J, Thorpe R, Pitts M. HIV Futures 5: Life as we know it, monograph series number 60. 2006, The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia.
79. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. *Family Planning Perspectives* 1999. 31: p. 272-279.
80. Weller SC, Davis KR. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev* 2002. (1): p. CD003255.
81. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. *Social Science and Medicine* 1997. 44: p. 1303-1312.
82. Weller SC. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. *Social Science and Medicine* 1993. 36(12): p. 1653-44.
83. Fitch TJ, Stine C, Hagar DW, Mann J, Adam MB, McIlhaney J. Condom Effectiveness: Factors that influence risk reduction. *Sexually Transmitted Diseases* 2002. 29: p. 811-817.
84. Alary M, Joly JR, Vincelette J, Lavoie R, Turmel B, Remis RS. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. *Am J Public Health* 2005. 95: p. 502-505.
85. Tahan V, Karaca C, Yildirim B, Bozbas A, Ozaras R, Demir K et al. Sexual transmission of HCV between spouses. *Am J Gastroenterol* 2005. 100: p. 821-824.

86. Terrault NA. Sexual activity as a risk factor for hepatitis C *Hepatology*, 2002. 36: p. S99-S105.
87. Australian Bureau of Statistics (3301.0 - Births, Australia, 2007) <http://www.abs.gov.au/AUSSTATS/abs@.nsf/mf/3301.0> (accessed 31 May, 2009).
88. Recent Increases in Australia's Fertility. 4102.0 - Australian Social Trends, 2007. <http://www.abs.gov.au/AUSSTATS/abs@.nsf/0/0FC193CDB42A241BCA25732C00206FBC?opendocument> (Accessed 31 May, 2009). 2009, Australian Bureau of Statistics.
89. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. *AIDS*, 1998. 12(2): p. 205-10.
90. Cooper ER, Nugent RP, Diaz C, Pitt J, Hanson C, Kalish LA et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. *J Infect Dis* 1996. 174(6): p. 1207-11.
91. Fiscus SA, Adimora AA, Schoenbach VJ, Lim W, McKinney R, Rupar D et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. *JAMA* 1996. 275(19): p. 1483-8.
92. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. *N Engl J Med* 1998. 339(20): p. 1409-14.
93. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. *Curr Pharm Des*, 2008. 14: p. 1646-1654.
94. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 2002. 36: p. S106-S113.
95. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis* 2005. 192: p. 1880-1889.
96. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex-models of disease transmission - an HIV model, as an example. *International Statistical Review* 1994. 62(2): p. 229-243.
97. Iman RL, Helton JC, Campbell JE. An Approach To Sensitivity Analysis Of Computer-Models .1. Introduction, Input Variable Selection And Preliminary Variable Assessment. *Journal Of Quality Technology* 1981. 13(3): p. 174.
98. Iman RL, Helton JC, Campbell JE. An approach to sensitivity analysis of computer-models .2. Ranking of input variables, response-surface validation, distribution effect and technique synopsis. *Journal of Quality Technology* 1981. 13(4): p. 232.
99. Iman RL, Helton JC. An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models. *Risk Analysis* 1988. 8(1): p. 71-90.
100. McKay MD, Conover WJ, Beckman RJ. A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code. *Technometrics* 1979. 21: p. 239-245.
101. Stein M. Large sample properties of simulations using Latin Hypercube Sampling. *Technometrics* 1987. 29: p. 143-151.
102. Handcock MS. Latin Hypercube Sampling to Improve the Efficiency of Monte Carlo Simulations: Theory and Implementation in ASTAP. IBM Research Division, TJ Watson Research Center, RC 14546. 1989.
103. Fedra K, Van Straten G, Beck MB. Uncertainty and arbitrariness in ecosystems modeling: A lake modeling example. *Ecological Modelling* 1981. 13: p. 87-110.
104. Rose KA, Smith EP, Gardner RH, Brenkert AL, Bartell SM. Parameter sensitivities, monte carlo filtering, and model forecasting under uncertainty. *Journal of Forecasting* 1991. 10: p. 117-133.
105. Saltelli A. Sensitivity Analysis for Importance Assessment. *Risk Analysis* 2002. 22(3): p. 579-590.
106. Rosner B. *Fundamentals of Biostatistics* (6th Ed.). 2006, Duxbury Press: Boston. p. 538-543.

107. Iman RL, Conover WJ. Small Sample Sensitivity Analysis Techniques for Computer-Models, With An Application To Risk Assessment. *Communications In Statistics Part A-Theory And Methods* 1980. 9(17): p. 1749.
108. Iman RL, Helton JC. An Investigation Of Uncertainty And Sensitivity Analysis Techniques For Computer-Models. *Risk Analysis* 1988. 8(1): p. 71.
109. McKay MD, Beckman RJ, Conover WJ. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. *Technometrics* 2000. 42(1): p. 55.
110. Blower SM, Hartel D, Dowlatabadi H, Anderson RM, May RM. Drugs, sex and HIV: a mathematical model for New York City. *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences*, 1991. 331(1260): p. 171-87.
111. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, Sanchez MA et al. The intrinsic transmission dynamics of tuberculosis epidemics. *Nat Med* 1995. 1(8): p. 815-21.
112. Porco TC, Blower SM. Quantifying the intrinsic transmission dynamics of tuberculosis. *Theoretical Population Biology* 1998. 54(2): p. 117-32.
113. Sanchez MA, Blower SM. Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example. *Am J Epidemiol* 1997. 145(12): p. 1127-37.
114. Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. *Clin Infect Dis* 2004. 39 Suppl 5: p. S240-7.
115. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. *Current Drug Targets: Infectious Disorders*, 2003. 3(4): p. 345-53.
116. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. *Nat Med* 2004. 10(10): p. 1111-6.
117. Breban R, McGowan I, Topaz C, Schwartz EJ, Anton P, Blower S. Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. *Mathematical Biosciences and Engineering* 2006. 3(3): p. 459-466.
118. Schroeder LD, Sqoquist DL, Stephan PE. *Understanding regression analysis*. 1986, Sage Publications. p. 31-32.
119. Saltelli A, Tarantola S. On the relative importance of input factors in mathematical models: Safety assessment for nuclear waste disposal. *J Am Stat Assoc* 2002. 97(459): p. 702-709.
120. Turanyi T, Rabitz H. Local methods and their applications, in *Sensitivity Analysis*, Saltelli A, Chan K, Scott M Editors. 2000, John Wiley: New York.
121. Varma A, Morbidelli M, Wu H. *Parametric Sensitivity in Chemical Systems*. 1999, Cambridge: Cambridge Series in Chemical Engineering.
122. Goldsmith CH. *Sensitivity Analysis*, in *Encyclopedia of Biostatistics*, Armitage P, Colton T Editors. 1998, John Wiley.
123. Campolongo F, Saltelli A, Jensen NR, Wilson J, Hjorth J. The Role of Multiphase Chemistry in the Oxidation of Dimethylsulphide (DMS). A Latitude Dependent Analysis. *J Atmospheric Chemistry* 1999. 32: p. 327-356.
124. Campolongo F, Tarantola S, Saltelli A. Tackling quantitatively large dimensionality problems. *Computer Physics Communications* 1999. 117: p. 75-85.
125. Kioutsioukis I, Tarantola S, Saltelli A, Gatelli D. Uncertainty and global sensitivity analysis of road transport emission estimates. *Atmospheric Environment* 2004. 38: p. 6609-6620.
126. Crosetto M, Tarantola S. Uncertainty and sensitivity analysis: tools for GIS-based model implementation. *International Journal of Geographic Information Science* 2001. 15(4): p. 415-437.
127. Pastorelli R, Tarantola S, Beghi MG, Bottani CE, Saltelli A. Design of surface Brillouin scattering experiments by sensitivity analysis *Surface Science* 2000. 468: p. 37-50.
128. Rabitz H. Efficient input-output model representations. *Computer Physics Communications* 1999. 117: p. 11-20.
129. Rabitz H, Ali OF. Managing the tyranny of parameters in mathematical modelling of physical systems, in *Sensitivity Analysis*, Saltelli A, Chan K, Scott M Editors. 2000, John Wiley: New York. p. 385-397.
130. Archer G, Saltelli A, Sobol IM. Sensitivity measures, ANOVA like techniques and the use of bootstrap. *J Statistical Computation and Simulation* 1997. 58: p. 99-120.

131. Hoare A, Regan DG, Wilson DP. Sampling and Sensitivity Analyses Tools (SaSAT) for Computational Models. *Theor Biol Med Model* 2008. 5:4.
132. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet* 2008. 372(9651): p. 1733-45.
133. Stoove MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). *Drug Alcohol Depend* 2008. 96(3): p. 281-5.
134. Abdala N, Gleghorn AA, Carney JM, Heimer R. Can HIV-1-Contaminated Syringes Be Disinfected? Implications for Transmission Among Injection Drug Users. *J Acq Imm Defic Syndr* 2001. 28(5): p. 487-494.
135. Siegel J, Weinstein M, Fineberg H. Bleach programs for preventing AIDS among IV drug users: modeling the impact of HIV prevalence. *Am J Public Health* 1991. 81(10): p. 1273-1279.
136. Abdala N, Crowe M, Tolstov Y, Heimer R. Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions. *Subst Use Misuse* 2004. 39(4): p. 581-600.
137. Hagan H, Thiede H. Does bleach disinfection of syringes help prevent hepatitis C virus transmission. *Epidemiology* 2003. 14(5): p. 628-629.
138. Agolini G, Russo A, Clementi M. Effect of phenolic and chlorine disinfectants on hepatitis C virus binding and infectivity. *Am J Infect Control* 1999. 27(3): p. 236-9.
139. Kapadia F, Vlahov D, Des Jarlais DC, Strathdee SA, Ouellet L, Kerndt P et al. Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users? *Epidemiology* 2002; 13(6): p. 738.
140. Syringe disinfection for Injection Drug Users 2007, Centers for Disease Control and Prevention
141. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. *Med J Aust* 1999;170:220-1.
142. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. *Int J Epidemiol* 2003. 32(5): p. 717-24.
143. Degenhardt L, Rendle V, Hall W, Gilmour S, Law W. Estimating the number of current regular heroin users in New South Wales and Australia 1997-2002. NDARC Technical Report No. 198 2004, Sydney: National Drug and Alcohol Research Centre.
144. Australian Institute of Health and Welfare, 2007 National Drug Strategy Household Survey: first results. 2008, Canberra: AIHW.
145. Australian demographic statistics. June 2008 Australian Bureau of Statistics (ABS).
146. MacDonald M, Zhou J. Australian NSP Survey National Data report 1995-2001. June 2002, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.
147. Australian Institute of Health and Welfare 2007, Statistics on drug use in Australia 2006. Drug Statistics Series No. 18. Cat. no. PHE 80. , Canberra: AIHW.
148. Australian Institute of Health and Welfare 2008, National Opioid Pharmacotherapy Statistical Annual Data (NOPSAD) Collection Data Guide: Data Items and Definitions 2007, IHW Working Paper. Cat. no. WP 60.Canberra: AIHW.
149. Australian Crime Commission (ACC) Australian illicit drug reports and Illicit drug data reports, 1996–2007.
150. Australian demographic statistics. December 2002, Australian Bureau of Statistics (ABS).
151. Smith C, d'Arminio Monforte A, de Wit S, Friis-Moller N, Lundgren J, Philips Andrew et al. Causes of death in the D:A:D study-initial results. 2008.
152. Degenhardt L, Rendle V, Hall W, Gilmour S, Law W. Mortality among dependent users of heroin and other opioids: Illicit Drugs Discussion Paper No. 9. 2008, National Drug and Alcohol Research Centre, University of New South Wales: Sydney.
153. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. *Addiction* 2008. 103(3): p. 462-8.
154. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. *Drug Alcohol Rev* 2007. 26(4): p. 405-10.

155. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. *AIDS* 2006. 20(6): p. 805-12.
156. Hudgens MG, Longini IM, Jr, Vanichseni S, Hu DJ, Kitayaporn D, Mock PA et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. *Am J Epidemiol* 2002. 155(2): p. 159-68.
157. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* 1997. 126(12): p. 946-54.
158. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet* 2004. 364(9428): p. 51-62.
159. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. *Lancet* 2007. 370(9585): p. 407-13.
160. Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study. *J Infect Dis* 2005. 192(8): p. 1387-1397.
161. Henderson DK, Fahey BJ, Willy M, Schmitt JM, Carey K, Koziol DE et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. *Ann Intern Med* 1990. 113(10): p. 740-6.
162. Cavalcante NJ, Abreu ES, Fernandes ME, Richtmann R, Piovesana MN, Yamada FT et al. Risk of health care professionals acquiring HIV infection in Latin America. *AIDS Care* 1991. 3(3): p. 311-6.
163. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. *J Infect Dis* 1994. 170(6): p. 1410-7.
164. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. *Arch Intern Med* 1993. 153(12): p. 1451-8.
165. Nelsing S, Nielsen TL, Nielsen JO. Occupational exposure to human immunodeficiency virus among health care workers in a Danish hospital. *J Infect Dis* 1994. 169(2): p. 478.
166. Tokars JI, Marcus R, Culver DH, Schable CA, McKibben PS, Bandea CI et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. *Ann Intern Med* 1993. 118(12): p. 913-9.
167. Patz JA, Jodrey D. Occupational health in surgery: risks extend beyond the operating room. *Aust N Z J Surg* 1995. 65(9): p. 627-9.
168. Kaplan EH, O'Keefe E. Let the needles do the talking! Evaluating the New Haven needle exchange. *Interfaces* 1993. 23(1): p. 7-26.
169. Peters L, Mocroft A, Soriano V, Rockstroh J, Jurgen K, Losso M et al. Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. *J Acq Imm Defic Syndr* 50(5)(April 2009): p. 457-463.
170. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S et al. Stability of antiretroviral regimens in patients with viral suppression. *AIDS* 2008. 22(9): p. 1039-46.
171. Short LJ, Bell Dm. Risk of occupational infection with blood-borne pathogens in operating and delivery room settings. *Am J Infect Control* 1993. 21(6): p. 343-50.
172. Gerberding JL. Management of Occupational Exposures to Blood-Borne Viruses. *N Engl J Med* 1995. 332(7): p. 444.
173. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. *Epidemiol Rev* 1996. 18(2): p. 137-48.
174. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K et al. Hepatitis C in hospital employees with needlestick injuries. *Ann Intern Med* 1991. 115(5): p. 367-9.
175. Sodeyama T, Kiyosawa K, Urushihara A, Matsumoto A, Tanaka E, Furuta S et al. Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents. *Arch Intern Med* 1993. 153(13): p. 1565-72.

176. Hamid SS, Farooqui B, Rizvi Q, Sultana T, Siddiqui AA. Risk of transmission and features of hepatitis C after needlestick injuries. *Infect Control Hosp Epidemiol* 1999. 20(1): p. 63-4.
177. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. *Infection* 2003. 31 Suppl 2: p. 22-7.
178. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. *Clin Infect Dis* 2006. 43(9): p. 1154-9.
179. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. *Hepatology* 2003. 37(1): p. 60-4.
180. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. *Hepatology* 2008. 48(2): p. 418-431.
181. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. *AIDS* 2008. 22(15): p. 1979-91.
182. Bruno R, Sacchi P, Puoti M, Maiocchi L, Patrino S, Carosi G et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. *J Acq Imm Defic Syndr* 2007. 46(3): p. 297-303.
183. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. *Hepatology* 1997. 25(3): p. 754-8.
184. Chiamonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. *Cancer* 1999. 85(10): p. 2132-7.
185. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut* 2000. 47(1): p. 131-6.
186. del Olmo JA, Serra MA, Rodriguez F, Escudero A, Gilabert S, Rodrigo JM. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. *J Cancer Res Clin Oncol* 1998. 124(10): p. 560-4.
187. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 1997. 112(2): p. 463-72.
188. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. *Am J Gastroenterol* 2002. 97(11): p. 2886-95.
189. Gentilini P, Laffi G, La Villa G, Romanelli RG, Buzzelli G, Casini-Raggi V et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. *Am J Gastroenterol* 1997. 92(1): p. 66-72.
190. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. *Hepatology* 1999. 29(4): p. 1311-6.
191. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. *Hepatology* 2005. 42(3): p. 711-23.
192. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *Hepatology* 1993. 18(1): p. 47-53.
193. Imberti D, Fornari F, Sbolli G, Buscarini E, Squassante L, Buscarini L. Hepatocellular carcinoma in liver cirrhosis. A prospective study. *Scand J Gastroenterol* 1993. 28(6): p. 540-4.
194. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. *Hepatology* 1998. 28(6): p. 1687-95.
195. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet* 1995. 346(8982): p. 1051-5.

196. Serfaty L, Aumaître H, Chazouillères O, Bonnard AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. *Hepatology* 1998. 27(5): p. 1435-40.
197. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. *Br J Cancer* 1997. 76(7): p. 968-74.
198. Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. *J Hepatol* 2004. 40(5): p. 823-30.
199. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. *J Viral Hepat* 2007. 14(8): p. 570-6.
200. Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. *Med Decis Making* 2004. 24(1): p. 20-9.
201. Annual Surveillance Report: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. 2008, National Centre in HIV Epidemiology and Clinical Research. Available at: [http://www.ncheer.unsw.edu.au/NCHECRweb.nsf/resources/Publications_3/\\$file/pub-nonpeer-rev.pdf](http://www.ncheer.unsw.edu.au/NCHECRweb.nsf/resources/Publications_3/$file/pub-nonpeer-rev.pdf)
202. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. *Hepatology* 1998. 28(3): p. 823-30.
203. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Long-term outcome of hepatitis C infection after liver transplantation. *N Engl J Med* 1996. 334(13): p. 815-20.
204. Hepatitis C Virus Projections Working Group : Estimates and projections of the Hepatitis C virus epidemic in Australia 2006. National Centre in HIV Epidemiology and Clinical Research.
205. Kamal SM. Acute hepatitis C: a systematic review. *Am J Gastroenterol* 2008. 103(5): p. 1283-97.
206. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002. 347(13): p. 975-82.
207. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001. 358(9286): p. 958-65.
208. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004. 351(5): p. 438-50.
209. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *J Viral Hepat* 2006. 13(1): p. 34-41.
210. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. *J Infect Dis* 2008. 198(9): p. 1337-44.
211. Piasecki BA, Lewis JD, Reddy KR, Bellamy SL, Porter SB, Weinrieb RM et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. *Hepatology* 2004. 40(4): p. 892-9.
212. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. *Can J Gastroenterol* 2007. 21(7): p. 447-51.
213. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. *Hepatology* 2006. 43(5): p. 923-31.
214. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. *Gastroenterology* 2006. 130(3): p. 632-8.

215. Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. *J Hepatol* 2005. 42(3): p. 323-8.
216. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Calleri G et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users. *Clin Infect Dis* 2007. 45(5): p. 583-8.
217. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. *J Antimicrob Chemother* 2006. 57(2): p. 360-3.
218. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. *AIDS* 2006. 20(8): p. 1157-61.
219. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. *J Viral Hepat* 2005. 12(2): p. 207-11.
220. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*, 2004. 140(5): p. 346-55.
221. Krawitt EL, Gordon SR, Grace ND, Ashikaga T, Ray MA, Palmer M et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. *Am J Gastroenterol* 2006. 101(6): p. 1268-73.
222. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2004. 292(23): p. 2839-48.
223. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N Engl J Med* 2004. 351(5): p. 451-9.
224. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. *AIDS* 2004. 18(13): p. F27-36.
225. Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. *J Viral Hepat* 2007. 14(4): p. 228-38.
226. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. *Liver Int* 2004. 24(6): p. 568-74.
227. Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernández C, Dehesa-Violante M, Maldonado-Garza H et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. *Ann Hepatol* 2003. 2(3): p. 135-9.
228. Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y et al. Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. *J Hepatol* 2007. 47(1): p. 51-9.
229. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. *J Viral Hepat* 2005. 12(3): p. 283-91.
230. Mimidis K, Papadopoulos VP, Elefsiniotis I, Kolioukas D, Ketikoglou I, Paraskevas E et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. *J Gastrointest Liver Dis* 2006. 15(3): p. 213-9.
231. Hurley SF, Kaldor JM, Carlin JB, Gardiner S, Evans DB, Chondros P et al. The usage and costs of health services for HIV infection in Australia. *AIDS* 1995. 9(7): p. 777-85.

232. Hurley SF, Kaldor JM, Gardiner S, Carlin JB, Assuncao RM, Evans DB. Lifetime cost of human immunodeficiency virus-related health care. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996. 12(4): p. 371-8.
233. Grierson J, Thorpe R, Pitts M. HIV FUTURES 5. The state of the positive nation. 2006, ARCSHS: Melbourne.
234. Garattini L, Tediosi F, Di Cintio E, Yin D, Parazzini F. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV* 2001. 13(6): p. 733-741.
235. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. *J Acquir Immune Defic Syndr* 2002. 30(1): p. 21-26.
236. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA et al. Distribution of health care expenditures for HIV-infected patients. *Clin Infect Dis* 2006. 42(7): p. 1003-10.
237. Medicare Statistics. 2008 15 April 2009; Available from: https://www.medicareaustralia.gov.au/statistics/mbs_item.shtml
238. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. *AIDS* 2004. 18(1): p. 51-8.
239. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002. 360(9327): p. 119-29.
240. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. *Med Care* 2005. 43(9 Suppl): p. III40-52.
241. Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. *J HIV Ther* 2006. 11(2): p. 36-8.
242. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Australian Commentary on DHHS Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2008.
243. Gold M, Siegel J, Russell L, Weinstein M. Cost effectiveness in Health and Medicine 1996, Oxford University Press, New York
244. Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect cost of HIV infection in England. *Clin Ther* 2000. 22(11): p. 1333-1345.
245. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. *Public Health Rep* 1987. 102(1): p. 5-17.
246. Sendi P, Schellenberg F, Ungsedhapand C, Kaufmann GR, Bucher HC, Weber R et al. Productivity costs and determinants of productivity in HIV-infected patients. *Clin Ther* 2004. 26(5): p. 791-800.
247. Organisation for Economic Cooperation and Development. Purchasing Power Parity 2008 [cited 2008; Available from: <http://www.oecd.org/dataoecd/61/54/18598754.pdf>.
248. PBAC, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). 2008, Australian Department of Health and Ageing: Canberra.
249. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. *J Health Econ* 1995. 14(2): p. 171-89.
250. Canadian Agency for Drugs and Technologies in Health. Guidelines for submissions. 2006.
251. Sendi P, Brouwer WB, Bucher HC, Weber R, Battagay M. When time is more than money: The allocation of time between work and leisure in HIV-infected patients. *Soc Sci Med*, 2007. 64(11): p. 2355-61.
252. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. *Med J Aust*, 1997. 167(1): p. 17-20.
253. Loxley W, Carruthers SJ, Bevan J. In the same vein: first report of the Australian study of HIV and injecting drug use. 1995, National Centre for Research into the Prevention of Drug Abuse, Curtin University, Perth.
254. HepCare Project. Report of a hepatitis C participant questionnaire in the Northern Sydney Area Health Service and the Hunter Area Health Service. Preliminary report. 1998.
255. Australian Bureau of Statistics, National Health Survey - (2004 - 05). , Australian Bureau of Statistics: Canberra.

256. Australian Bureau of Statistics, Employee earnings, benefits and Trade Union Membership 2003.
257. Magnus A, Mihalopoulos C, Carter R. Department of Treasury and Finance. Evaluation of Preventive Health Interventions. 2008, Deakin University: Burwood.
258. J Grierson, R Thorpe and M Pitts. HIV Futures 5: Life as we know it. 2006, monograph series number 60, The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia.
259. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT et al. Survival of Persons with and without HIV Infection in Denmark, 1995-2005. *Ann Intern Med* 2007. 146(2): p. 87-95.
260. Day CA, White B, Thein HH, Doab A, Dore GJ, Bates A et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. *AIDS Care* 2008. 20: p. 116-123.
261. White B, Day C, Thein HH, Doab A, Bates A, Holden J et al. Acceptability of hepatitis C virus testing methods among injecting drug users. *Drug Alcohol Rev* 2008: p. 1-5.